1901 related articles for article (PubMed ID: 16180941)
1. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
2. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
4. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
Durrieu G; Olivier P; Montastruc JL;
Eur J Clin Pharmacol; 2005 Sep; 61(8):611-4. PubMed ID: 16133552
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
Brinker A; Goldkind L; Bonnel R; Beitz J
Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714
[TBL] [Abstract][Full Text] [Related]
6. Renal failure associated with the use of celecoxib and rofecoxib.
Ahmad SR; Kortepeter C; Brinker A; Chen M; Beitz J
Drug Saf; 2002; 25(7):537-44. PubMed ID: 12093311
[TBL] [Abstract][Full Text] [Related]
7. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
8. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature.
Ward KE; Archambault R; Mersfelder TL
Am J Health Syst Pharm; 2010 Feb; 67(3):206-13. PubMed ID: 20101062
[TBL] [Abstract][Full Text] [Related]
9. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
[TBL] [Abstract][Full Text] [Related]
10. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
Phelan KM; Mosholder AD; Lu S
J Clin Psychiatry; 2003 Nov; 64(11):1328-34. PubMed ID: 14658947
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.
Papay J; Yuen N; Powell G; Mockenhaupt M; Bogenrieder T
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):289-96. PubMed ID: 22139991
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
[TBL] [Abstract][Full Text] [Related]
13. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
[TBL] [Abstract][Full Text] [Related]
14. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
15. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
16. Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
Xu C; Pan L; Zhang Y; Zhang J; Sun Q; Fang W
Int J Clin Pract; 2021 Aug; 75(8):e14273. PubMed ID: 33908133
[TBL] [Abstract][Full Text] [Related]
17. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides].
Aberer W; Stingl G; Wolff K
Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320
[TBL] [Abstract][Full Text] [Related]
18. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.
Lugardon S; Lapeyre-Mestre M; Montastruc JL
Eur J Clin Pharmacol; 2004 Nov; 60(9):673-7. PubMed ID: 15517227
[TBL] [Abstract][Full Text] [Related]
19. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
[TBL] [Abstract][Full Text] [Related]
20. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports.
Sanchez-Matienzo D; Arana A; Castellsague J; Perez-Gutthann S
Clin Ther; 2006 Aug; 28(8):1123-1132. PubMed ID: 16982289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
